Smartleaf Asset Management LLC Buys 2,397 Shares of Danaher Corporation $DHR

Smartleaf Asset Management LLC lifted its stake in Danaher Corporation (NYSE:DHR) by 37.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,754 shares of the conglomerate’s stock after purchasing an additional 2,397 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Danaher were worth $1,629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of DHR. WFA of San Diego LLC bought a new position in shares of Danaher during the second quarter valued at $26,000. Howard Hughes Medical Institute purchased a new position in Danaher in the 2nd quarter worth about $27,000. TruNorth Capital Management LLC purchased a new position in Danaher in the 3rd quarter worth about $28,000. Tripletail Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at about $31,000. Finally, Heartwood Wealth Advisors LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at about $37,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

NYSE DHR opened at $216.77 on Monday. The business’s fifty day moving average is $229.62 and its 200 day moving average is $215.17. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87. The company has a market capitalization of $153.12 billion, a PE ratio of 43.01, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping the consensus estimate of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s dividend payout ratio is presently 25.40%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. This represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 11.20% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several research reports. Evercore reissued an “outperform” rating and set a $254.00 price objective on shares of Danaher in a report on Wednesday, January 28th. The Goldman Sachs Group decreased their target price on shares of Danaher from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. HSBC raised their price target on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Argus set a $265.00 price objective on Danaher in a research report on Wednesday, January 14th. Finally, Leerink Partners raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research report on Friday, January 16th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.86.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.